These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 18589126)
21. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Opelz G; Döhler B; Transplantation; 2009 Mar; 87(6):795-802. PubMed ID: 19300179 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK. McEwan P; Dixon S; Baboolal K; Conway P; Currie CJ Pharmacoeconomics; 2006; 24(1):67-79. PubMed ID: 16445304 [TBL] [Abstract][Full Text] [Related]
23. Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis. Wollenberg A; Sidhu MK; Odeyemi I; Dorsch B; Koehne-Volland R; Schaff M; Ehlken B; Berger K Br J Dermatol; 2008 Dec; 159(6):1322-30. PubMed ID: 18782316 [TBL] [Abstract][Full Text] [Related]
24. Cardiovascular risk factors in renal transplant patients after switch from standard tacrolimus to prolonged-release tacrolimus. Sessa A; Esposito A; Iavicoli G; Lettieri E; Ragosta G; Rossano R; Capuano M Transplant Proc; 2012 Sep; 44(7):1901-6. PubMed ID: 22974866 [TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of once-daily vs twice-daily tacrolimus among Hispanic and Black kidney transplant recipients. Hurwitz JT; Grizzle AJ; Tyler CS; Zapata LV; Malone DC J Manag Care Spec Pharm; 2021 Jul; 27(7):948-960. PubMed ID: 34185556 [No Abstract] [Full Text] [Related]
26. Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation. Glander P; Waiser J; Kasbohm S; Friedersdorff F; Peters R; Rudolph B; Wu K; Budde K; Liefeldt L Clin Transplant; 2018 Aug; 32(8):e13311. PubMed ID: 29888809 [TBL] [Abstract][Full Text] [Related]
27. Tacrolimus effects and side effects after liver transplantation: is there a difference between immediate and extended release? Weiler N; Thrun I; Eberlin M; Foltys D; Heise M; Hoppe-Lotichius M; Zimmermann T; Kraemer I; Otto G Transplant Proc; 2013; 45(6):2321-5. PubMed ID: 23953543 [TBL] [Abstract][Full Text] [Related]
36. A 6-month, multicenter, single-arm pilot study to evaluate the efficacy and safety of generic tacrolimus (TacroBell) after primary renal transplantation. Kim SJ; Huh KH; Han DJ; Moon IS; Kim SJ; Kim YL; Kim HC; Lee S; Kang CM; Cho BH; Kim YS Transplant Proc; 2009 Jun; 41(5):1671-4. PubMed ID: 19545705 [TBL] [Abstract][Full Text] [Related]
37. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial. Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF; Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398 [TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of a new combined immunosuppressive and anti-infectious regimen in kidney transplantation. Wasserfallen JB; Kast-Brückner M; Manuel O; Venetz JP; Meylan PR; Pascual M Int J Technol Assess Health Care; 2008; 24(3):312-7. PubMed ID: 18601799 [TBL] [Abstract][Full Text] [Related]
39. Kidney transplantation with corticosteroid-free maintenance immunosuppression: a single center analysis of graft and patient survivals. Filipe R; Mota A; Alves R; Bastos C; Macário F; Figueiredo A; Roseiro A; Parada B; Sá H; Nunes P; Bastos M Transplant Proc; 2009 Apr; 41(3):843-5. PubMed ID: 19376367 [TBL] [Abstract][Full Text] [Related]
40. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial. Radakovic S; Breier-Maly J; Konschitzky R; Kittler H; Sator P; Hoenigsmann H; Tanew A J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):951-3. PubMed ID: 19496898 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]